Diaceutics has partnered with Canadian Pathology Quality Assurance (CPQA) for advancing neurotrophic tropomyosin receptor kinase (NTRK) immunohistochemical (IHC) proficiency testing (PT) development across the world.
Recently, NTRK gene fusions have been targeted for cancer therapy.
More labs worldwide are testing NTRK, which means there is a growing demand for a robust PT programme, Diaceutics noted.
By identifying the need to source Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks from laboratories, CPQA will help them build a small tissue microarray for NTRK IHC PT and the development of validation assistance.
As part of the collaboration, CPQA will use Diaceutics’ DXRX market place to offer the testing to a global network of precision medicine diagnostics, which include laboratories near its facility.
CPQA aims to support the implementation of accurate and high-quality testing, focusing mainly on curating secretory breast carcinoma and / or salivary mammary analogue secretory carcinoma (MASC) blocks.
These tissue types have a higher incidence of NTRK fusions.
CPQA director John Garratt said: “We are looking forward to taking advantage of Diaceutics’ extensive network facilitated through DXRX. This will enable us to engage with labs globally in developing quality assurance material for biomarker testing to ensure accurate delivery of personalised therapeutics.”
In addition, having to work with the global external quality assessment (EQA) or PT providers, the laboratories, which participate in the collaboration hosted on the DXRX platform, can also participate in the CPQA pan-TRK EQA programme free of charge.
Diaceutics senior director Karina Hjort said: “A DXRX collaboration is an opportunity for multiple stakeholders to work together to solve real-world testing challenges at any stage of the diagnostic development and commercialisation process, either by joining sponsored collaborations or creating their own on the marketplace.”